| Title |
Acceptance of a reusable self-injection device for recombinant human growth hormone: final data from a questionnaire-based, cross-sectional, international, multicenter, observational study in pediatric patients
|
|---|---|
| Published in |
Medical Devices : Evidence and Research, September 2016
|
| DOI | 10.2147/mder.s115933 |
| Pubmed ID | |
| Authors |
Dirk Schnabel, Carl-Joachim Partsch, Muriel Houang, Sarah Ehtisham, Helen Johnstone, Markus Zabransky, Wieland Kiess |
| Abstract |
A questionnaire-based survey was conducted to assess attitudes toward a reusable self-injection system (SurePal™) among pediatric patients with growth disturbances who were prescribed treatment with Omnitrope(®) within routine clinical practice. This was a multicenter, observational study, incorporated into the noninterventional PAtients TReated with Omnitrope(®) (PATRO) Children study. Included subjects, or their caregivers, completed a questionnaire on the following five main areas: attractiveness of SurePal™, training received, using the device, the low drug wastage system, and experience versus other devices used previously (pretreated patients). Responses were based on a 5-point scale, with 2 being the best possible outcome and -2 the worst possible outcome. In total, 550 patients were included in this study (338 from France, 169 from Germany, and 43 from the UK). The mean age ± standard deviation of participants was 10.8±3.5 years; the majority (57%) were male and growth hormone treatment naïve (88%). Almost half (49.8%) of children prepared their SurePal™ for injection themselves and 45.5% performed injections themselves. As patients progressed into their teens, the majority (≥75%) favored preparing SurePal™ and performing injections themselves, rather than seeking assistance. The attractiveness of SurePal™ was rated as excellent/good by 84.7% of patients overall; this rating was similarly high (≥79%) across countries and age-groups. Preparing (88.8%) and using (83.3%) SurePal™ were rated as very easy/easy by most patients; these ratings were similarly high, irrespective of country or age-group. The dose-memory function was rated as very helpful/helpful by 66.2% of patients. Among 246 patients who reported using the low drug-waste feature, 87.4% found it helpful. Among pretreated patients (n=64), 78.2% reported that SurePal™ was much better/better than their previous device. These data confirm the ease of use and patient preference for SurePal™ among pediatric patients with growth disturbances. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 14% |
| Unknown | 6 | 86% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 71% |
| Practitioners (doctors, other healthcare professionals) | 2 | 29% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 4 | 19% |
| Student > Doctoral Student | 4 | 19% |
| Lecturer > Senior Lecturer | 1 | 5% |
| Student > Bachelor | 1 | 5% |
| Researcher | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 9 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 19% |
| Psychology | 2 | 10% |
| Nursing and Health Professions | 2 | 10% |
| Engineering | 2 | 10% |
| Social Sciences | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 10 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2022.
All research outputs
#6,786,204
of 25,584,565 outputs
Outputs from Medical Devices : Evidence and Research
#82
of 303 outputs
Outputs of similar age
#98,135
of 348,930 outputs
Outputs of similar age from Medical Devices : Evidence and Research
#5
of 15 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 303 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.7. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,930 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.